Odyssey Therapeutics, Inc. ODTX
—
20.51
0.58
2.91%
as of 25 Sep
- Market cap
- $957.8M
- P/E
- 0.0×
Follow ODTX
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Jun '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+1 more quarter Free account |
0.00 | — | — | — |
P/S ratio |
0.00 | — | — | — | |
P/FCF ratio |
0.00 | — | — | — | |
P/Operating CF |
(2.26) | — | — | — | |
P/B ratio |
0.00 | — | — | — | |
Price to Tangible BV |
0.00 | — | — | — | |
EV/Sales |
0.00 | — | — | — | |
EV/EBITDA |
0.00 | — | — | — | |
EV/Operating CF |
0.00 | — | — | — | |
EV/FCF |
0.00 | — | — | — | |
Quick Ratio |
— | 6.85 | 7.91 | 10.98 | |
Current Ratio |
— | 7.20 | 8.33 | 11.36 | |
Net Debt/EBITDA |
0.00 | 0.00 | 4.55 | 5.71 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
— | — | — | 0.00 | |
Operating CF/Net income |
0.83 | — | 1.07 | 0.65 | |
Capex/Depreciation |
0.04 | — | (0.13) | 0.09 | |
Interest Coverage |
0.00 | — | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
3,151.93% | — | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
1,378.42% | — | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.05 | 0.06 | 0.03 | |
Share Based Compensation of Revenue |
385.61% | — | 0.00% | 0.00% | |
Graham Net Nets |
1.46 | — | — | — | |
Graham Number |
0.00 | — | — | — | |
Earnings Yield |
(413.84%) | — | — | — | |
Free Cash Flow Yield |
0.00% | — | — | — | |
Revenue per Share |
0.69 | — | 0.00 | 0.00 | |
Operating CF per Share |
(24.55) | — | (7.26) | (1.14) | |
Capex per Share |
0.04 | — | (0.03) | 0.00 | |
Free Cash Flow per Share |
(24.51) | — | (7.28) | (1.14) | |
Cash per Share |
0.00 | 0.00 | 31.07 | 10.26 | |
Shareholders Equity per Share |
0.00 | 0.00 | 31.80 | 13.91 | |
Interest Debt per Share |
0.00 | — | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 31.80 | 13.91 | |
Free Cash Flow |
(34.21) | — | (41.18) | (34.41) | |
Working Capital |
— | 164.18 | 162.89 | 293.17 | |
Capital Expenditures |
0.06 | — | (0.15) | 0.10 | |
Net Current Asset Value |
0.00 | 136.15 | 135.90 | 258.83 | |
EV/EBIT |
0.00 | — | — | — | |
Capex to Sales |
(0.06) | — | 0.00 | 0.00 | |
Net Profit Margin |
(4,299.79%) | — | 0.00% | 0.00% | |
Price to Operating Income |
0.00 | — | — | — | |
| Other line items | |||||
Average Assets |
— | — | — | 241.93 |
Columns are period end dates